BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, Higa F, Takahashi H, Yoshida M, Kohno S, Kaneko T. Adjunctive Systemic Corticosteroids for Hospitalized Community-Acquired Pneumonia: Systematic Review and Meta-Analysis 2015 Update. Sci Rep. 2015;5:14061. [PMID: 26374694 DOI: 10.1038/srep14061] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Rello J, Perez A. Precision medicine for the treatment of severe pneumonia in intensive care. Expert Rev Respir Med 2016;10:297-316. [PMID: 26789703 DOI: 10.1586/17476348.2016.1144477] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
2 Phua J, Dean NC, Guo Q, Kuan WS, Lim HF, Lim TK. Severe community-acquired pneumonia: timely management measures in the first 24 hours. Crit Care 2016;20:237. [PMID: 27567896 DOI: 10.1186/s13054-016-1414-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
3 Odeyemi YE, Herasevich S, Chalmers SJ, Barreto EF, Frank RD, Gajic OO, Yadav H. Biomarker-Concordant Steroid Use in Critically Ill Patients with Pneumonia. Mayo Clin Proc Innov Qual Outcomes 2020;4:649-56. [PMID: 33367210 DOI: 10.1016/j.mayocpiqo.2020.07.011] [Reference Citation Analysis]
4 Chalmers S, Khawaja A, Wieruszewski PM, Gajic O, Odeyemi Y. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers. World J Crit Care Med 2019;8:59-71. [PMID: 31559145 DOI: 10.5492/wjccm.v8.i5.59] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
5 Fitzgerald DB, Waterer GW, Read CA, Fysh ET, Shrestha R, Stanley C, Muruganandan S, Lan NSH, Popowicz ND, Peddle-McIntyre CJ, Rahman NM, Gan SK, Murray K, Lee YCG. Steroid therapy and outcome of parapneumonic pleural effusions (STOPPE): Study protocol for a multicenter, double-blinded, placebo-controlled randomized clinical trial. Medicine (Baltimore) 2019;98:e17397. [PMID: 31651842 DOI: 10.1097/MD.0000000000017397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Song Y, Yao C, Yao Y, Han H, Zhao X, Yu K, Liu L, Xu Y, Liu Z, Zhou Q, Wang Y, Ma Z, Zheng Y, Wu D, Tang Z, Zhang M, Pan S, Chai Y, Song Y, Zhang J, Pan L, Liu Y, Yu H, Yu X, Zhang H, Wang X, Du Z, Wan X, Tang Y, Tian Y, Zhu Y, Wang H, Yan X, Liu Z, Zhang B, Zhong N, Shang H, Bai C. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial. Crit Care Med. 2019;47:e735-e743. [PMID: 31162191 DOI: 10.1097/ccm.0000000000003842] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 56.0] [Reference Citation Analysis]
7 Laterre PF, Sánchez-García M, van der Poll T, de la Rosa O, Cadogan KA, Lombardo E, François B. A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit. BMC Pulm Med 2020;20:309. [PMID: 33238991 DOI: 10.1186/s12890-020-01324-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Nora D, Nedel W, Lisboa T, Salluh J, Póvoa P. The role of steroids in severe CAP. Hosp Pract (1995) 2020;48:12-22. [PMID: 31977280 DOI: 10.1080/21548331.2020.1720215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pirofski LA, Casadevall A. Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage. Antimicrob Agents Chemother 2020;64:e01800-19. [PMID: 31740558 DOI: 10.1128/AAC.01800-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 . Corticosteroids in Community-Acquired Pneumonia. JAMA 2020;323:887-8. [PMID: 32027338 DOI: 10.1001/jama.2020.0216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sparham S, Charles PG. Controversies in diagnosis and management of community-acquired pneumonia. Med J Aust 2017;206:316-9. [PMID: 28403766 DOI: 10.5694/mja16.01463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019;2:CD010406. [PMID: 30798570 DOI: 10.1002/14651858.CD010406.pub3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
13 Garnacho-montero J, Barrero-garcía I, Gómez-prieto MDG, Martín-loeches I. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Review of Anti-infective Therapy 2018;16:667-77. [DOI: 10.1080/14787210.2018.1512403] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
14 Horita N, Otsuka T, Haranaga S, Namkoong H, Miki M, Miyashita N, Higa F, Takahashi H, Yoshida M, Kohno S, Kaneko T. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis. Respirology 2016;21:1193-200. [PMID: 27338144 DOI: 10.1111/resp.12835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
15 Martino EA, Baiardo Redaelli M, Sardo S, Lembo R, Giordano VF, Winterton D, Ruggeri L, Hajjar LA, Zangrillo A, Landoni G. Steroids and Survival in Critically Ill Adult Patients: A Meta-analysis of 135 Randomized Trials. J Cardiothorac Vasc Anesth 2018;32:2252-60. [PMID: 29793761 DOI: 10.1053/j.jvca.2018.04.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit Care Med. 2020;48:e98-e106. [PMID: 31939808 DOI: 10.1097/ccm.0000000000004093] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 74.0] [Reference Citation Analysis]
17 Pereira JM, Lisboa T, Paiva J. Adjuvant therapies in critical care: steroids to treat infectious diseases. Intensive Care Med 2018;44:1306-9. [DOI: 10.1007/s00134-017-5020-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Waterer G. Systemic corticosteroids and community-acquired pneumonia-cautious optimism or wishful thinking? J Thorac Dis 2015;7:E622-4. [PMID: 26793375 DOI: 10.3978/j.issn.2072-1439.2015.12.22] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Chan ED, Chan MM, Chan MM, Marik PE. Use of glucocorticoids in the critical care setting: Science and clinical evidence. Pharmacology & Therapeutics 2020;206:107428. [DOI: 10.1016/j.pharmthera.2019.107428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
20 Sabbagh DK, Barmayehvar B, Nguyen T, Edgar RG, Turner AM. Managing panniculitis in alpha-1 antitrypsin deficiency: Systematic review of evidence behind treatment. WJD 2018;7:1-8. [DOI: 10.5314/wjd.v7.i1.1] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
21 Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, Niederman M, Wunderink RG. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med 2019;45:159-71. [PMID: 30706119 DOI: 10.1007/s00134-019-05519-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 17.0] [Reference Citation Analysis]
22 Briel M, Spoorenberg SMC, Snijders D, Torres A, Fernandez-serrano S, Meduri GU, Gabarrús A, Blum CA, Confalonieri M, Kasenda B, Siemieniuk RA, Boersma W, Bos WJW, Christ-crain M; Ovidius Study Group, Capisce Study Group and STEP Study Group. Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. Clinical Infectious Diseases 2018;66:346-54. [DOI: 10.1093/cid/cix801] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
23 Torres A, Ferrer M, Niederman MS. Adjuvant therapies in critical care: steroids in community-acquired pneumonia. Intensive Care Med 2018;44:478-81. [PMID: 29071427 DOI: 10.1007/s00134-017-4967-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
24 Wang J, Song YL. Advances in severe community-acquired pneumonia. Chin Med J (Engl) 2019;132:1891-3. [PMID: 31335475 DOI: 10.1097/CM9.0000000000000366] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Severiche-Bueno D, Parra-Tanoux D, Reyes LF, Waterer GW. Hot topics and current controversies in community-acquired pneumonia. Breathe (Sheff) 2019;15:216-25. [PMID: 31508159 DOI: 10.1183/20734735.0205-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
26 Lloyd M, Karahalios A, Janus E, Skinner EH, Haines T, De Silva A, Lowe S, Shackell M, Ko S, Desmond L, Karunajeewa H; Improving Evidence-Based Treatment Gaps and Outcomes in Community-Acquired Pneumonia (IMPROVE-GAP) Implementation Team at Western Health. Effectiveness of a Bundled Intervention Including Adjunctive Corticosteroids on Outcomes of Hospitalized Patients With Community-Acquired Pneumonia: A Stepped-Wedge Randomized Clinical Trial. JAMA Intern Med 2019;179:1052-60. [PMID: 31282921 DOI: 10.1001/jamainternmed.2019.1438] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
27 Chalmers S, Khawaja A, Wieruszewski PM, Gajic O, Odeyemi Y. Diagnosis and treatment of acute pulmonary inflammation in critically ill patients: The role of inflammatory biomarkers. WJCCM 2019;8:74-96. [DOI: 10.5492/wjccm.v8.i5.74] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
28 Ceccato A, Ferrer M, Barbeta E, Torres A. Adjunctive Therapies for Community-Acquired Pneumonia. Clinics in Chest Medicine 2018;39:753-64. [DOI: 10.1016/j.ccm.2018.07.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
29 Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane Database Syst Rev 2017;12:CD007720. [PMID: 29236286 DOI: 10.1002/14651858.CD007720.pub3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
30 Wiemken TL, Kelley RR, Fernandez-Botran R, Mattingly WA, Arnold FW, Furmanek SP, Restrepo MI, Chalmers JD, Peyrani P, Cavallazzi R, Bordon J, Aliberti S, Ramirez JA. Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study. Univ Louisville J Respir Infect 2017;1:3-11. [PMID: 28393141 DOI: 10.18297/jri/vol1/iss1/1/] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
31 Wu W, Fang Q, He G. Efficacy of corticosteroid treatment for severe community-acquired pneumonia: A meta-analysis. The American Journal of Emergency Medicine 2018;36:179-84. [DOI: 10.1016/j.ajem.2017.07.050] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
32 Okumura T, Kawada J, Tanaka M, Narita K, Ishiguro T, Hirayama Y, Narahara S, Tsuji G, Sugiyama Y, Suzuki M, Tsuji T, Hoshino S, Nakatochi M, Muramatsu H, Kidokoro H, Takahashi Y, Sato Y, Miyajima Y, Uno N, Nagai N, Ando S, Sudo Y, Naruse K, Takahashi Y, Suzui R, Nagata Y, Kawabe T, Shibata M, Shibata Y, Morishita M, Kajita M, Ito T, Kido S, Hasegawa S, Ikeda K, Tokumo N, Kato M, Kato K, Fukumi D, Doi S, Omori M, Watanabe N, Takada H. Comparison of high-dose and low-dose corticosteroid therapy for refractory Mycoplasma pneumoniae pneumonia in children. Journal of Infection and Chemotherapy 2019;25:346-50. [DOI: 10.1016/j.jiac.2019.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019;200:e45-67. [PMID: 31573350 DOI: 10.1164/rccm.201908-1581ST] [Cited by in Crossref: 772] [Cited by in F6Publishing: 345] [Article Influence: 772.0] [Reference Citation Analysis]
34 Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, Richards GA, van Zyl Smit R, Smith C, Wasserman S, Whitelaw AC, Feldman C; South African Thoracic Society., Federation of Infectious Diseases Societies of Southern Africa. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis 2017;9:1469-502. [PMID: 28740661 DOI: 10.21037/jtd.2017.05.31] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
35 Feldman C, Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis 2016;8:E162-71. [PMID: 27076965 DOI: 10.21037/jtd.2016.02.43] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
36 Bi J, Yang J, Wang Y, Yao C, Mei J, Liu Y, Cao J, Lu Y. Efficacy and Safety of Adjunctive Corticosteroids Therapy for Severe Community-Acquired Pneumonia in Adults: An Updated Systematic Review and Meta-Analysis. PLoS One 2016;11:e0165942. [PMID: 27846240 DOI: 10.1371/journal.pone.0165942] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
37 Martin-Loeches I, Torres A. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm? Eur Respir Rev 2021;30:200346. [PMID: 33568526 DOI: 10.1183/16000617.0346-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Waterer G, Metersky ML. Corticosteroids for Community-Acquired Pneumonia: Overstated Benefits and Understated Risks. Chest 2019;156:1049-53. [PMID: 31287999 DOI: 10.1016/j.chest.2019.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]